Clinical Trials Browser

Withdrawn × durvalumab × Thoracic × Clear all

NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1 Withdrawn

Lung Neoplasms

NCT04889066 2024-12-20

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05757843 2024-09-19

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04944173 2024-09-03

SCION

Phase 2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Phase 1 Withdrawn

Lung Neoplasms

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Phase 2 Withdrawn

Lung Neoplasms

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04470674 2022-03-03

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

NCT04262869 2021-10-27

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04262375 2020-11-17

DOMINATION

Phase 2 Withdrawn

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04262388 2020-11-17

DOME

Phase 2 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02673814 2016-08-01

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung